Company intelligence / Profile preview
scPharmaceuticals Inc.
Burlington, Massachusetts, United Statesscpharmaceuticals.com ↗
- Ownership
- Public · SCPH
- Development stage
- Other
01
Overview
scPharmaceuticals has successfully commercialized FUROSCIX (furosemide injection), which received FDA approval for heart failure in 2022 and expanded indication for chronic kidney disease in March 2025. The company reported $36.3 million in revenue for full year 2024, with approximately 41,000 FUROSCIX doses filled in 2024.
- Therapeutic areas
- CardiovascularNephrology
- Modalities
- Drug-device combinations
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Late-stage cardiovascular and renal R&D companies
Beyond the preview
Go deeper on scPharmaceuticals Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on scPharmaceuticals Inc..